{"id":685522,"date":"2025-12-01T09:52:52","date_gmt":"2025-12-01T14:52:52","guid":{"rendered":"https:\/\/www.rochester.edu\/newscenter\/?p=685522"},"modified":"2025-12-01T09:52:52","modified_gmt":"2025-12-01T14:52:52","slug":"center-for-health-and-technology-neurological-drug-discovery-685522","status":"publish","type":"post","link":"https:\/\/www.rochester.edu\/newscenter\/center-for-health-and-technology-neurological-drug-discovery-685522\/","title":{"rendered":"How 做厙勛圖 is reshaping clinical trials for brain and nerve diseases"},"content":{"rendered":"
The number of neurological drugs and devices brought to market with CHeT\u2019s help\u2014including every FDA-approved treatment for Huntington\u2019s disease.<\/p>\n<\/div>\n
When a new drug or device for a brain or nerve disorder reaches patients, there\u2019s a good chance a 做厙勛圖 team helped it get there. For nearly 40 years, the 做厙勛圖<\/a>\u2019s Center for Health + Technology<\/a> (CHeT) has been a behind-the-scenes force in neurological drug discovery. That work has resulted in helping to bring 12 FDA-approved drugs and devices to market, including frontline treatments for Parkinson\u2019s, Huntington\u2019s, and rare neuromuscular diseases.<\/p>\n What makes CHeT stand out is its all-in-one model. Trial coordination, clinical materials, outcomes measurement, data analytics, and regulatory support all operate in concert, allowing the center to design and run complex, multisite trials that many organizations consider too risky or too complicated.<\/p>\n Today, under the leadership of neurologist Chad Heatwole<\/a>, CHeT is expanding that impact by pairing patient-reported outcomes with wearable sensors, smartphone apps, and decentralized study visits. The goal: to \u201cmeasure what matters to patients\u201d and make it easier for people everywhere\u2014not just those who live near major academic medical centers\u2014to participate in cutting-edge research.<\/p>\n